Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BMS acquired Karuna Therapeutics for $14B for schizophrenia treatment KarXT.
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal. The centerpiece of the acquisition is KarXT, an antipsychotic with a…
ARISE Phase 3 (adjunctive Cobenfy to atypical antipsychotics) missed primary endpoint: 2.0-pt PANSS reduction vs placebo, p=0.11 (not significant). Tempers the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
BMS acquired Karuna Therapeutics for $14B for schizophrenia treatment KarXT.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Karuna Therapeutics (this deal) | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. | 2022 | $4.1B | 70 |
← Browse all deals · How we score deals
More: 2023 deals · Bristol-Myers Squibb Company deals · Neurology deals